Board summary
Key figures
36,166
Registered population
58.0% aged 18–64
22.3%
Aged 65+
ICB 21.9% · England 17.9%
7.3%
Ethnic minority (non-White)
2.6% Asian · England 9.6%
4.3%
In IMD quintile 1
ICB 9.2% · England 21.0%
~1,426
Core20 residents (est.)
Resident basis; registered basis ~1,680 · see page 3
6,479
Hypertension register
+4.43% in 3 yrs · England +5.60%
517
SMI register
40.8% of Lewes'
905
COPD register
Reviews +56.26% in 3 yrs
Forecast to 2030
7,425
Hypertension patients, 2030
+946 on today
63.9%
QRISK ≥20% on statins, 2030
+3.45pp over 3 yrs
5.5%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
CVD treatment to target lags England.
QRISK >= 20% lipid therapy is 56.3% (England 63.6%) and hypertension treatment to target is 64.6% (England 70.3%), which may reflect unescalated therapy.
Dementia and stroke registers contracted over 2023-2025.
Dementia prevalence changed -11.1% (England +6.0%) and stroke -1.0% (England +2.3%) over 2023 to 2025, which could reflect unverified coding or case-finding gaps.
Respiratory reviews and BP control rose strongly.
Over 2023 to 2025, asthma reviews rose +74.7% (England +4.4%), COPD reviews rose +56.3% (England +2.8%), and under-80 BP control rose +9.3 pp.
Population, age and ethnicity
Older residents comprise 22.3% of the PCN, exceeding England's 17.9% list share
Across 36,166 registered patients, 22.3% are aged 65+, below Lewes (25.9%) but above NHS Sussex Integrated Care Board (21.9%) and England (17.9%). Children aged 0-17 comprise 19.7% (Lewes 17.7%, NHS Sussex Integrated Care Board 17.7%, England 19.6%). Census resident ethnicity, which reflects catchment areas rather than registered lists, is 92.7% White (Lewes 94.2%, NHS Sussex Integrated Care Board 91.0%, England 81.1%) and 2.6% Asian / Asian British (Lewes 1.9%, NHS Sussex Integrated Care Board 3.7%, England 9.6%). Primary list size is projected to grow 3.0% by 2030 (Lewes 2.3%, NHS Sussex Integrated Care Board 2.1%, England 2.3%), under unverified methodology.
Age profile
65+: ICB 21.9%, England 17.9%
Ethnicity
Older people · falls rows are Lewes local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Lewes LA) | 2,359 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 80.0% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 56.3% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Lewes LA) | 1,111 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Lewes LA) | 15.2 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
Deprivation is concentrated in two practices while PCN Core20 is 4.3%
The PCN average IMD decile is 4.4 (Lewes 6.2, England 5.5). The PCN Core20 share is 4.3% (Lewes 2.9%, England 21.0%), while weighted practice Core20 is 4.6% (a 0.36 pp reconciliation difference). Practice distribution spans an 11.4 pp range: Chapel Street Surgery has the highest concentration at 11.4% (estimated 576 patients), while Quayside Medical Practice holds the largest volume at 9.2% (estimated 1,104 patients). Havenshealth records 0.0%.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
517
SMI register
1.42% recorded prevalence
232
Learning disability register
0.64% recorded prevalence
10
Care homes, 161 beds
In the PCN catchment
9.9%
Provide unpaid care
Lewes, Census 2021
The PCN records 517 patients on the severe mental illness register (1.4% vs Lewes 1.4%, NHS Sussex Integrated Care Board 1.1%, England 1.0%), accounting for 40.8% of the borough register, and 232 on the learning disability register (0.6%). The PCN catchment includes 10 care homes with 161 beds.
Severe mental illness: physical health checks
SMI blood pressure recording reached 86.3% (England 83.4%), while BMI recording was 81.8% (England 82.1%) and smoking cessation support was 90.4% (England 94.2%). At Chapel Street Surgery, recorded BMI checks were 58.0%.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
6,479
Hypertension register
+4.43%
Register growth, 3 yrs
Lewes +5.23% · England +5.60%
+9.27pp
BP control, under 80
≤140/90 · +5.89pp aged 80+
+946
More patients by 2030
Forecast 7,425 (19.36%)
Hypertension case-finding and control
Hypertension register prevalence is 17.8% (6,479 patients), above England (15.2%) and NHS Sussex Integrated Care Board (16.3%), but below Lewes (18.1%). Recent blood pressure recording reached 89.5% (England 90.0%). Blood pressure control among patients aged under 80 improved by +9.3 pp over three years (England +2.1 pp) to 65.1%, though it remains below England (67.8%) and varies from 59.2% at Chapel Street Surgery to 67.7% at Havenshealth. Observation periods were not supplied for recorded prevalence. Lower blood pressure control than national benchmarks suggests an opportunity to prioritise systematic medication titration and recall across practices trailing the England rate.
Lipids and statins
For patients with QRISK ≥ 20%, 56.3% receive lipid-lowering therapy, in line with Lewes (56.2%) but below England (63.6%) and NHS Sussex Integrated Care Board (60.0%). Fewer at-risk primary prevention patients receive lipid-lowering therapy than national rates imply, presenting an opportunity to prioritise proactive treatment reviews for high-risk cohorts.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 61,651 | £2.50 | £2.42 | £1.86 | £154,128 |
| Cardiovascular (all), 2025 | 88,235 | £3.20 | £3.32 | £3.33 | £282,352 |
In 2026, lipid-modifying drugs cost £2.50 per item across 61,651 items, compared to £2.34 in Lewes, £2.42 in NHS Sussex Integrated Care Board, and £1.86 in England, which is £39,457 more than at England's unit cost. Higher unit cost than national benchmarks highlights an opportunity to audit formulary choices and switch to cost-effective lipid-modifying regimens.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+74.65%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+1.61%
Asthma prevalence, PCN 3-yr % change
Asthma reviews rose +74.7% over three years (England +4.4%) to 65.5% (England 65.7%, Lewes 57.0%), leaving an estimated 945 unreviewed patients of 2,740 on the register. COPD reviews rose +56.3% (England +2.8%) to 73.5% (England 76.4%). Paediatric asthma prescribing reached 1,872 items per 1,000 aged 5–19 (England 1,488, Lewes 1,696), while second-hand smoke recording was 72.2% (England 78.8%). This pattern could reflect unreviewed triggers or inhaler regimens, unverified locally and testable by clinical audit.
Cancer register and children's immunisation
Cancer QOF prevalence is 4.6% (1,670 patients; England 3.8%, Lewes 5.6%). For childhood immunisations in Q1 2025/26, MMR dose 1 coverage at 24 months is 89.7% (England 88.3%), below the 95.0% target by 5.3 pp. At age 5, MMR dose 2 coverage is 90.7% (England 82.8%) with a 3.7 pp difference from dose 1 (94.4%), while 4-in-1 pre-school booster coverage is 89.8%.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
58.5%
Sussex ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~1,360
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Sussex ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Prostate | 56.6% | 53.2% | 19% | 1,668 |
| Breast | 86.1% | 85.4% | 23% | 1,400 |
| Bowel | 49.8% | 47.0% | 26% | 1,133 |
| Lung | 30.3% | 33.8% | 15% | 1,058 |
| Skin cancer | 95.3% | 87.8% | 17% | 698 |
In NHS Sussex ICB, 58.5% of staged cancers (4,799 of 8,209) were diagnosed at stage 1 or 2 in 2022, 16.5 pp below the 75.0% national ambition, although above England (55.3%). Known-stage data covered 64.3% of 12,766 registered cases; ICB figures reflect system pathways rather than PCN performance. Reaching 75.0% would require about 1,360 extra early-stage diagnoses across the ICB. Locally, cervical screening uptake among women aged 25-49 is 68.1% (England 66.8%, Lewes 69.8%) but fell 3.8% over 2023 to 2025 (England -1.0%), down to 64.7% at Chapel Street Surgery.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In July 2026 (provisional), University Hospitals Sussex NHS Foundation Trust achieved 65.2% on the 62-day cancer referral to treatment standard (standard 85.0%), below East Sussex Healthcare NHS Trust (67.0%), Maidstone and Tunbridge Wells NHS Trust (87.4%), NHS Surrey and Sussex Integrated Care Board (71.5%), and England (71.2%). On the 28-day faster diagnosis standard (standard 75.0%), the trust reached 74.0%, below East Sussex Healthcare NHS Trust (84.2%), Maidstone and Tunbridge Wells NHS Trust (81.8%), and both the ICB and England (79.3%). Diagnostic 6+ week waits reached 12.9% overall, with colonoscopy at 39.3% (East Sussex Healthcare NHS Trust 0.7%, England 30.8%).
| Pathways within standard (%) | Sussex | East Sussex Healthcare | Maidstone and Tunbridge Wells | Surrey and Sussex ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 74.01 | 84.20 | 81.78 | 79.29 | 79.32 |
| 31-day treatment (96%) | 76.79 | 98.19 | 98.35 | 90.45 | 92.50 |
| 62-day referral to treatment (85%) | 65.20 | 67.04 | 87.43 | 71.51 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Sussex | East Sussex Healthcare | Maidstone and Tunbridge Wells | England |
|---|---|---|---|---|
| MRI | 5.62 | 6.48 | 0.92 | 21.40 |
| CT | 8.57 | 0.48 | 0.51 | 9.92 |
| Echocardiography | 0.39 | 21.94 | 2.57 | 28.48 |
| Colonoscopy | 39.35 | 0.74 | 19.80 | 30.83 |
| Gastroscopy | 20.02 | 0.31 | 24.03 | 29.02 |
| All 15 DM01 tests | 12.95 | 5.27 | 6.42 | 23.14 |
| Community services activity | East Sussex residents | Surrey and Sussex ICB |
|---|---|---|
| Care contacts | 100,740 | 309,615 |
| Referrals | 17,285 | 66,930 |
| Patients with a contact | 25,880 | 85,660 |
Community services (residents of East Sussex), Jun 2026 (provisional). In June 2026 (provisional), community health services recorded 105,045 care activities and 100,740 contacts for East Sussex residents, alongside 316,320 activities and 309,615 contacts across NHS Surrey and Sussex Integrated Care Board. Contacts with adults aged 65+ accounted for 68% of the borough residents' total (68,465 contacts). These experimental figures reflect broad system activity rather than unique PCN patient contacts.
Practice variation and patient experience
Patient experience spans 14.9 pp across practices, alongside marked variations in access
In 2025/26, QOF overall achievement reached 94.0% at Havenshealth, 91.1% at Quayside Medical Practice, and 90.2% at Chapel Street Surgery (England 92.5%). Vaccination and immunisation achievement showed wider variation, spanning 13.9 pp from 43.5% at Chapel Street Surgery to 57.4% at Havenshealth (England 55.2%). High overall scores may mask specific preventive delivery gaps across practices.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Havenshealth | 109 | 0.0 | 42.0% | 80.5% | 74.0% |
| Quayside Medical | 109 | 9.2 | 50.1% | 73.2% | 73.8% |
| Chapel Street | 105 | 11.4 | 48.9% | 66.7% | 59.1% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Dementia fell 11.1% and stroke fell 1.0% over three years while England grew
Over 2023 to 2025, dementia QOF prevalence fell 11.1% (England +6.0%, Lewes -6.0%) and stroke fell 1.0% (England +2.3%, Lewes +1.4%), while heart failure functional capacity reviews grew +2.9% (England +8.7%, Lewes +13.5%). Conversely, recorded delivery achieved major gains: asthma reviews rose +74.7% (England +4.4%), COPD reviews rose +56.3% (England +2.8%), and severe mental illness blood pressure checks increased +12.0 pp (England +4.4 pp). This pattern could reflect coding or diagnostic backlogs, unverified locally and testable by register audit.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Dementia register
Heart failure reviews
COPD register
Stroke register
Depression register
Asthma reviews
COPD reviews
BP control, under 80
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Lewes | Asset | PCN | Lewes |
|---|---|---|---|---|---|
| Care homes (catchment) | 10 (161 beds) | n/a | Schools (catchment) | 25 | n/a |
| Children's centres | 1 | 2 | Places of worship | 24 | 76 |
| Libraries | 1 | 3 | Homelessness support (VCS) | 0 | no data |
| Primary schools (LA maintained) | 5 | 16 | Primary academies | 4 | 9 |
| Special schools | n/a | 2 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
CVD treatment and prescribing review
Hypertension treatment to target is 64.6% (England 70.3%) across 6,479 patients; QRISK >= 20% lipid therapy is 56.3% (England 63.6%); 2026 lipid-modifying prescribing costs £2.50 per item vs £1.86 in England (£39,457 more across 61,651 items). Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 2
Asthma annual review and prescribing recall
Asthma review coverage is 65.5% (England 65.7%, Lewes 57.0%), leaving an estimated 945 unreviewed of 2,740 patients; 5-19 prescribing is 1,872 items per 1,000 (England 1,488) and second-hand smoke recording is 72.2% (England 78.8%). Low cost, quick to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 3
Stroke and dementia register validation
Over 2023 to 2025, dementia prevalence fell 11.1% (England +6.0%; 309 patients, 0.8% vs Lewes 1.1%, gap -26 to +96) and stroke fell 1.0% (England +2.3%; 819 patients, 2.2% vs Lewes 2.6%, gap -136 to +135). Low cost, quick to run.
Evidence base: the stroke/TIA register is the cohort for AF anticoagulation and blood-pressure control (pre-stroke prevention) as well as hyperacute care; practices well below expected prevalence are the case-finding list, and the pre-stroke prevention gap concentrates in deprived practices.
Policy anchor: Core20PLUS5 (CVD); NHS CVD ambitions to 2029.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Older adult care coordination (p2) | Aged 65+ | Neighbourhood health framework · NHS vaccination strategy | PCN |
| Targeted Core20 practice outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI health check audit (p4) | Smoking cessation support and treatment offered to patients with certain conditions (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN |
| Hypertension treatment review (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Childhood immunisation recall (p6) | MMR dose 1 coverage at 24 months | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall audit (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Practice access and triage review (p9) | GPPS good overall experience of the practice | 10YHP, hospital to community | Practice |
| Option 1 · CVD treatment and prescribing review (p12) | Hypertension register · Hypertension patients treated to target · Patients with QRISK ≥ 20% treated with lipid lowering therapy | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN & Practice |
| Option 2 · Asthma annual review and prescribing recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · Asthma management items prescribed per 1000 5-19 Population | Core20PLUS5 respiratory | PCN |
| Option 3 · Stroke and dementia register validation (p12) | Stroke register · Stroke: QOF prevalence · Dementia register | Core20PLUS5 CVD · CVDPREVENT · SSNAP · 66.7% diagnosis ambition · 95% care plan 2027 | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
